Insmed director Sharoky sells $637,650 of Insmed stock
What it means
- What to watch: The headline hangs on one number ($637,650) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $INSM +13.94% in the latest session.
- Timing: It arrived overnight — the change beside it belongs to a session that had already packed up and gone home. Market holidays are not detected.
Where the stock stands
$INSM last changed hands at $110.50, +13.94% on the session, 48% below its 52-week high of $212.75 and 22% above its low of $90.39 — in the lower part of the range. Over the year it has ranged 135% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $INSM page.
How much coverage it is getting
Wook has logged 3 stories on $INSM in the last 30 days, 1 of them this week. At its 30-day pace you would expect about 1 a week, so this week is somewhat busier than usual. Across those stories 0 read bullish, 1 neutral and 2 bearish. This one reads neutral, so it sits with a sizeable part of the run — it has company, but it is not the consensus. 2 of the 3 (67%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$INSM earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
For the receipts, the $INSM page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $INSM sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $INSM. It carried $637,650, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 3, 2026. $INSM has moved -12.77% ($126.68 to $110.50). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.